Provided by Tiger Fintech (Singapore) Pte. Ltd.

Castle Biosciences, Inc.

18.54
-0.7300-3.79%
Post-market: 18.540.00000.00%16:04 EDT
Volume:581.56K
Turnover:10.76M
Market Cap:535.29M
PE:-100.50
High:19.36
Open:19.12
Low:18.08
Close:19.27
Loading ...

Lake Street Reaffirms Their Buy Rating on Castle Biosciences (CSTL)

TIPRANKS
·
Yesterday

Castle Biosciences enters collaboration, license agreement with SciBase

TIPRANKS
·
Yesterday

Castle Biosciences Inc. Announces Collaboration with SciBase for Development of Diagnostic Test Predicting Atopic Dermatitis Flares

Reuters
·
Yesterday

Castle Biosciences Inc - Scibase to Receive $5 Mln Milestone Payment When Castle Sales Reach $50 Mln Annually

THOMSON REUTERS
·
Yesterday

Castle Biosciences Inc - Scibase to Defer Clinical Development Costs for Initial Indication

THOMSON REUTERS
·
Yesterday

Castle Biosciences Inc - Scibase to Receive Single-Digit Royalty and Double-Digit Mark-up on Sales

THOMSON REUTERS
·
Yesterday

Castle Biosciences Enters Collaboration and License Agreement With Scibase to Develop Diagnostic Tests for Dermatologic Diseases

THOMSON REUTERS
·
Yesterday

Castle Biosciences CEO Derek Maetzold to Participate in Panel Discussion at 2025 BIO International Convention

Reuters
·
11 Jun

Castle Biosciences Inc. Conducted Annual Stockholders Meeting

Reuters
·
24 May

Castle Biosciences Is Maintained at Sector Outperform by Scotiabank

Dow Jones
·
21 May

Castle Biosciences price target lowered to $40 from $44 at Scotiabank

TIPRANKS
·
21 May

Castle Biosciences Inc. to Present at the 2025 Jefferies Global Healthcare Conference

Reuters
·
21 May

U.S. RESEARCH ROUNDUP-Levi Strauss, Myriad Genetics, Palo Alto

Reuters
·
21 May

Castle Biosciences Is Maintained at Buy by Lake Street

Dow Jones
·
07 May

Stock Track | Castle Biosciences (CSTL) Plummets 14.21% as Q1 Earnings Fall Short of Expectations

Stock Track
·
06 May

Castle Biosciences Is Maintained at Buy by Canaccord Genuity

Dow Jones
·
06 May

Stock Track | Castle Biosciences (CSTL) Plunges 6.13% Pre-market on Q1 Earnings Miss

Stock Track
·
06 May

Castle Biosciences to acquire Capsulomics, terms undisclosed

TIPRANKS
·
06 May

Castle Biosciences Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
06 May

Castle Biosciences raises FY25 revenue view to $287M-$297M from $280M-$295M

TIPRANKS
·
06 May